<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36397190</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1523-2859</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>1664</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>The Medical letter on drugs and therapeutics</Title><ISOAbbreviation>Med Lett Drugs Ther</ISOAbbreviation></Journal><ArticleTitle>Relyvrio for ALS.</ArticleTitle><Pagination><StartPage>190</StartPage><EndPage>191</EndPage><MedlinePgn>190-191</MedlinePgn></Pagination><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Lett Drugs Ther</MedlineTA><NlmUniqueID>2985240R</NlmUniqueID><ISSNLinking>0025-732X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Buphenyl</Keyword><Keyword MajorTopicYN="N">Radicava</Keyword><Keyword MajorTopicYN="N">Relyvrio</Keyword><Keyword MajorTopicYN="N">Rilutek</Keyword><Keyword MajorTopicYN="N">adverse effects</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">dosage</Keyword><Keyword MajorTopicYN="N">drug interactions</Keyword><Keyword MajorTopicYN="N">edaravone</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">lactation</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">riluzole </Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">sodium phenylbutyrate</Keyword><Keyword MajorTopicYN="N">taurursodiol </Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>0</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36397190</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>